Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study
Standard
Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study. / Rostock, Matthias; Fischer, Julia; Mumm, Andreas; Stammwitz, Ute; Saller, Reinhard; Bartsch, Hans Helge.
in: GYNECOL ENDOCRINOL, Jahrgang 27, Nr. 10, 10.2011, S. 844-8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study
AU - Rostock, Matthias
AU - Fischer, Julia
AU - Mumm, Andreas
AU - Stammwitz, Ute
AU - Saller, Reinhard
AU - Bartsch, Hans Helge
PY - 2011/10
Y1 - 2011/10
N2 - OBJECTIVE: The antihormonal therapy of breast cancer patients with the antiestrogen tamoxifen often induces or aggravates menopausal complaints. As estrogen substitution is contraindicated, herbal alternatives, e.g. extracts of black cohosh are often used.DESIGN: A prospective observational study was carried out in 50 breast cancer patients with tamoxifen treatment. All patients had had surgery, most of them had undergone radiation therapy (87%) and approximately 50% had received chemotherapy. Every patient was treated with an isopropanolic extract of black cohosh (1-4 tablets, 2.5 mg) for 6 months. Patients recorded their complaints before therapy and after 1, 3, and 6 months of therapy using the menopause rating scale (MRS II).RESULTS: The reduction of the total MRS II score under black cohosh treatment from 17.6 to 13.6 was statistically significant. Hot flashes, sweating, sleep problems, and anxiety improved, whereas urogenital and musculoskeletal complaints did not change. In all, 22 patients reported adverse events, none of which were linked with the study medication; 90% reported the tolerability of the black cohosh extract as very good or good.CONCLUSIONS: Black cohosh extract seems to be a reasonable treatment approach in tamoxifen treated breast cancer patients with predominantly psychovegetative symptoms.
AB - OBJECTIVE: The antihormonal therapy of breast cancer patients with the antiestrogen tamoxifen often induces or aggravates menopausal complaints. As estrogen substitution is contraindicated, herbal alternatives, e.g. extracts of black cohosh are often used.DESIGN: A prospective observational study was carried out in 50 breast cancer patients with tamoxifen treatment. All patients had had surgery, most of them had undergone radiation therapy (87%) and approximately 50% had received chemotherapy. Every patient was treated with an isopropanolic extract of black cohosh (1-4 tablets, 2.5 mg) for 6 months. Patients recorded their complaints before therapy and after 1, 3, and 6 months of therapy using the menopause rating scale (MRS II).RESULTS: The reduction of the total MRS II score under black cohosh treatment from 17.6 to 13.6 was statistically significant. Hot flashes, sweating, sleep problems, and anxiety improved, whereas urogenital and musculoskeletal complaints did not change. In all, 22 patients reported adverse events, none of which were linked with the study medication; 90% reported the tolerability of the black cohosh extract as very good or good.CONCLUSIONS: Black cohosh extract seems to be a reasonable treatment approach in tamoxifen treated breast cancer patients with predominantly psychovegetative symptoms.
KW - Adult
KW - Aged
KW - Antineoplastic Agents, Hormonal/adverse effects
KW - Anxiety/chemically induced
KW - Breast Neoplasms/drug therapy
KW - Cimicifuga/chemistry
KW - Estrogen Antagonists/adverse effects
KW - Female
KW - Hot Flashes/chemically induced
KW - Humans
KW - Menopause/drug effects
KW - Middle Aged
KW - Patient Dropouts
KW - Phytotherapy/adverse effects
KW - Plant Extracts/adverse effects
KW - Rhizome/chemistry
KW - Selective Estrogen Receptor Modulators/adverse effects
KW - Sleep Wake Disorders/chemically induced
KW - Sweating/drug effects
KW - Tamoxifen/adverse effects
U2 - 10.3109/09513590.2010.538097
DO - 10.3109/09513590.2010.538097
M3 - SCORING: Journal article
C2 - 21231853
VL - 27
SP - 844
EP - 848
JO - GYNECOL ENDOCRINOL
JF - GYNECOL ENDOCRINOL
SN - 0951-3590
IS - 10
ER -